Profil
Andreas Buchbender is currently working as a Portfolio Manager at Medical Strategy GmbH since 2023.
Previously, he worked as a Scientific Assistant at Max Planck Institut für Pflanzenzüchtungsforschung from 2011 to 2013.
Dr. Buchbender completed his undergraduate and graduate degrees at the University of Hannover in 2016 and 2017 respectively.
He obtained his doctorate degree from The Johannes Gutenberg University of Mainz in 2021.
Aktiva positioner av Andreas Buchbender
| Företag | Position | Start |
|---|---|---|
Medical Strategy GmbH
Medical Strategy GmbH Investment ManagersFinance MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health. MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research | Analyst-Equity | 2020-11-01 |
Tidigare kända positioner av Andreas Buchbender
| Företag | Position | Slut |
|---|---|---|
Max Planck Institut für Pflanzenzüchtungsforschung
Max Planck Institut für Pflanzenzüchtungsforschung Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | 2013-01-01 |
Andreas Buchbenders utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Medical Strategy GmbH
Medical Strategy GmbH Investment ManagersFinance MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health. MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research | Finance |
University of Hannover
University of Hannover Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johannes Gutenberg University of Mainz
The Johannes Gutenberg University of Mainz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max Planck Institut für Pflanzenzüchtungsforschung
Max Planck Institut für Pflanzenzüchtungsforschung Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















